|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.91 USD | -2.35% |
|
-7.03% | -30.88% |
| May. 02 | CUREVAC : A missed opportunity |  |
| Apr. 26 | UBS Cuts CureVac Price Target to $14 From $18, Maintains Buy Rating | MT |
CureVac N.V. reported earnings results for the nine months ended September 30, 2022. For the nine months, the company reported sales was EUR 55.73 million compared to EUR 61.77 million a year ago. Net loss was EUR 120.25 million compared to EUR 409.78 million a year ago.
Basic loss per share from continuing operations was EUR 0.64 compared to EUR 2.21 a year ago. Diluted loss per share from continuing operations was EUR 0.64 compared to EUR 2.21 a year ago.
| 1st Jan change | Capi. | |
|---|---|---|
| -30.88% | 667M | |
| +17.96% | 47.02B | |
| +48.77% | 41.86B | |
| +1.17% | 41.76B | |
| -4.27% | 28.8B | |
| +11.42% | 26.05B | |
| -21.39% | 19.15B | |
| +4.86% | 12.55B | |
| +27.29% | 12.34B | |
| -3.50% | 11.82B |
CUREVAC N.V. 
